Fluidic Analytics

In-solution measurement of antibody affinities and binding stoichiometries to neurotoxic amyloid species

ROLAND WORTH[1], VIOLA DENNINGER[1], SEAN DEVENISH[1], SEBASTIAN FIEDLER[1] AND TUOMAS KNOWLES[1,2]

1 FLUIDIC ANALYTICS, CAMBRIDGE, UNITED KINGDOM

2 CENTRE FOR MISFOLDING DISEASES, YUSUF HAMIED DEPARTMENT OF CHEMISTRY, UNIVERSITY OF CAMBRIDGE, CAMBRIDGE, UNITED KINGDOM

Abstract

Microfluidic Diffusional Sizing (MDS) quantifies and characterizes any protein interaction – even in complex backgrounds, even with challenging targets. In this application note, we utilize MDS to measure size, affinity and stoichiometry of protein complexes formed by antibodies and amyloid oligomers or fibrils. Such comprehensive characterization of an antibody's interaction fingerprint is crucial to evaluate specificity and mechanism of action. Based on affinity, the specificity of a drug antibody can be assessed, for example, binding to neurotoxic aggregates vs. the monomeric (often non-toxic) species of the same protein. Stoichiometry is essential to determine the frequency of an epitope which relates to a drug antibody's mechanism of action. Moreover, our assay is very easy to perform, takes less than 3 hours in total, and requires only 3.5 μL per data point.

Introduction

Formation of neurotoxic amyloid aggregates and their gradual accumulation in the brain are hallmarks of most neurodegenerative diseases (ND). While many efforts have been made to develop suitable therapeutics, to date there is no cure, and existing treatments only focus on reducing the symptoms and maintaining the quality of life of patients.

Immunotherapy approaches against ND focus on antibodies that specifically target the pathogenic oligomeric or fibrillar forms of proteins like α-synuclein (Parkinson's disease) or Aβ peptide (Alzheimer's disease). Accurate characterization of the interaction between antibodies and these aggregate species, however, proves to be challenging for most technologies.

For this reason, ELISA-based assays are still the method of choice to distinguish antibodies targeting conformational epitopes on the surface of oligomers or fibrils from those that bind to monomers. In a direct ELISA, monomers, oligomers, or fibrils are immobilized and tested for antibody binding (Figure 1). This approach, however, risks heterogeneous exposure of target epitopes due to surface immobilization.


Direct ELISA	Competition ELISA	MDS
Each species immobilized	**Monomer immobilized**	**Immobilization-free**
• Loss of information through surface-induced conformational bias	• No K_D or stoichiometry	• K_D → specificity
• No K_D or stoichiometry	• Challenging competition experiment	• Stoichiometry → mechanism of action
• Assay development required	• Assay development required	• Biological samples (CSF, serum)
		• Quick and easy to perform

Figure 1. Unlike ELISA, MDS uniquely measures the most crucial parameters (affinity and stoichiometry) to assess antibody specificity and mechanism of action.

Another common ELISA assay to evaluate antibody specificity utilizes a competition format in which antibodies compete between surface-bound monomers and monomers, oligomers, and fibrils in solution. While this format measures the crucial interactions in solution and is thus less prone to surface-induced conformational heterogeneity it cannot provide universally comparable K_D values or stoichiometry which are essential to elucidate the mechanism of action of a drug candidate.

As shown in the case of aducanumab (Linse et al. 2020), a therapeutic antibody against Alzheimer's disease, efficacy can be linked to stoichiometry of binding as revealed by MDS. Specifically, a more frequently exposed epitope causes oligomers or fibrils to be covered with antibody which impairs neurotoxicity of these amyloid aggregates.

In this application note, we explain the principle of this new MDS assay including workflow, timings, and sample consumption using as an example a monoclonal antibody that binds to α-synuclein monomers, oligomers, and fibrils.

Crucially, the assay only takes 2–3 hours, is immobilization-free, provides universally comparable K_D values to assess specificity, and determines stoichiometry which is required to investigate the mechanism of action.

Reference: Linse et al., J., *Nature Struct. Mol. Biol.*, **2020**, 27, 1125–1133. DOI: 10.1038/s41594-020-0505-6

Results

To characterize the binding properties of 4D6 antibody to α-synuclein monomers, oligomers, and fibrils, it was first titrated against the monomeric form of α-synuclein. Using MDS, the hydrodynamic radius (R_h) of the free labeled α-synuclein monomer was measured to be 3.18 (± 0.12) nm (Figure 2). In the presence of antibody, the Rh was 5.01 (± 0.10) nm, therefore confirming complex formation. The measured sizes are typical of intrinsically disordered α-synuclein binding to a monoclonal antibody.

Using our cloud-based Bayesian MAAP application, values were obtained for K_D and stoichiometry (Figure 2). The results are presented as probability distributions with the mode (peak maximum) being the best estimate for K_D and the width representing the uncertainty (error) associated with this value. The K_D for monomer binding of 4D6 was determined to be 11.4 nM with a 95% highest density interval (HDI; similar to a 95% confidence interval) from 3.4 nM to 17.6 nM (Figure 2).

In addition to K_D, our assay simultaneously determines the binding stoichiometry in terms of how many monomers per antibody form the complex. In practice, this is achieved by simultaneously fitting the concentration of binding sites available for the fluorescently labeled species. The monomer stoichiometry is then calculated by the following equation

$$\text{stoichiometry}_{mon} = [\text{binding sites}]/[\text{antibody}]\text{total}.$$

In the case of 4D6 binding to monomer the stoichiometry is 2.2 (95% HDI 1.6–2.8) monomers per antibody as expected for antigen binding to a monoclonal IgG (Figure 2).

The ability of 4D6 to bind to other forms of α-synuclein was determined by measuring equilibrium binding of fluorescently labeled 4D6 antibody and unlabeled α-synuclein oligomers or fibrils (Figure 2). In the presence of the α-synuclein oligomers or α-synuclein fibrils, the R_h of the complex was 7.86 (± 0.31) nm and 12.13 (± 0.38) nm, respectively. Thus, the antibody–fibril complex was considerably larger than the antibody–oligomer complex, confirming that R_h measurement by MDS is ideally suited to confirm the antibody bound to the species of interest.

The affinities of 4D6 to oligomers and fibrils were very similar to those measured for monomer. While these binding experiments confirm that 4D6 binds various forms of α-synuclein with high affinity, our results suggest that the antibody likely binds to an epitope that is exposed at a similar level in the monomer, oligomers, and fibrils.

We also determined binding stoichiometries of 4D6 to α-synuclein oligomers and fibrils. Unlike for the monomer experiments, binding to oligomers and fibrils was measured with fluorescently labeled antibody which is why the stoichiometry in terms of monomers per antibody is calculated as

$$\text{stoichiometry}_{olig}/\text{fib} = [\alpha\text{-synuclein}]\text{total}/[\text{binding sites}].$$

The stoichiometry values were 5.5 (95% HDI 3.7 - 8.2) and 7.1 (95% HDI 3.9 – 12.0) for oligomers and fibrils. These values can be interpreted as 1 antibody being bound every 5-6 α-synuclein monomers within an oligomer and 1 antibody being bound every 7 α-synuclein monomers within a fibril. These reduced binding stoichiometries relative to the monomer, suggest that within the oligomers and fibrils some monomers are unavailable for antibody binding, as would be expected.

Figure 2. Binding of 4D6 antibody to α-synuclein monomers, oligomers, and fibrils. The modes of the probability distributions represent the best-fit estimates for K_D and stoichiometry.

Conclusion

Here we show that by using our novel in-solution assay based on MDS, we can accurately distinguish the binding targets for antibodies against amyloid aggregates such as α-synuclein monomer, oligomers, or fibrils. Crucially, the assay determines affinity and stoichiometry which are essential to evaluate antibody specificity and mechanism of action. Our in-solution assay takes less than 3 hours and uses low microgram amounts of protein.

Workflow overview

2-3 hours (includes sample equilibration)

1-2 hours	10 min	5 min	25 min	5 min	25 min
Pre-measurement • Antibody labeling • Fibril sonication (not required for oligomers)	**Sample preparation** • Mixing of binding partners in solution • Compatible with common buffers	**Sample transfer** • 3.5 μL of sample and flow buffer per sample port	**Sample measurement** • Binding curve 12 data points in duplicate • Starting from 5 μM unlabeled • 5 nM labeled antibody	**Data analysis** • Easy-to-use cloud-based application • Suggests additional measurements if required	**Additional measurement** • 1-2 iterations usually required • Ensures high precision of results

Assay specifications:

- Quick and easy to perform
- Unique interaction fingerprint
- K_D range from pM to μM
- Provides stoichiomtetry (monomer/antibody)

- Amount of antibody 1-10 μg depending on affinity
- Amount of oligomer or fibril 10-25 μg
- 12 μL of sample per triplicate
- Use of complex backgrounds (CSF, serum, lysates)

Methods

Using a NanoDrop One™, the concentration of the α-synuclein monomer (ab218818, Abcam), oligomer (SPR-466B, 2BScientific) and fibrils (SPR-322B, 2BScientific) were determined in PBS (pH 7.4) by using the absorbance at 205 nm and an extinction coefficient of ε_{205} = 31 mL.mg⁻¹.cm⁻¹, while the concentration of the 4D6 antibody (ab1903, Abcam) was determined in PBS (pH 7.4) at 280 nm using the IgG template (Thermo Fisher Scientific). For labeling, the α-synuclein monomer and 4D6 antibody were diluted into labeling buffer (0.2 M $NaHCO_3$, pH 8.3) and mixed with Alexa Fluor™ 647 NHS ester (Thermo Fisher Scientific) at a dye-to-protein ratio of 3:1. Following incubation overnight at 4 °C, the labeled 4D6 antibody was purified using a 1 mL Pierce® Desalting Column (Thermo Fisher Scientific) with PBS (pH 7.4) as the elution buffer, while the labeled α-synuclein monomer was instead purified on an ÄKTA protein-chromatography system equipped with a Superdex™ 75 Increase 10/300 GL column (Cytiva, 29-1487-21) at a flow-rate of 0.5 mL.min-1 using PBS (pH 7.4) as a buffer.

Prior to MDS measurement, a fresh batch of oligomers was thawed and used directly. Fibrils were sonicated prior to use to improve their homogeneity. Thawed fibrils were sonicated in a volume of 220 μL and a concentration of 0.56 mg.mL⁻¹ using a Branson SFX150 Sonifier® (Fisher Scientific) using 20 s pulses for 6 min at an intensity of 80%. After sonication, the fibrils were centrifuged at 13000 x g for 20 min at 20 °C then filtered through a 0.22 μm Millex®-GV low protein binding Durapore® (PVDF) membrane filter. The concentration of the oligomers and fibrils were determined for each batch prior to use and in all cases refer to the concentration of the α-synuclein monomers making up the sample.

For affinity measurements to the monomeric form of α-synuclein, the 4D6 antibody was diluted in PBS/0.05% Tween 20 (PBST) to give concentrations between 0.63–80 nM (2-fold dilutions). 4D6 was mixed with the fluorescently labeled α-synuclein monomer to give a final monomer concentration of 5 nM followed by incubation at 4 °C for 30 min. For affinity measurements to either the α-synuclein oligomers or fibrils, these were serially diluted in PBST to achieve concentrations of 3.5 nM–3.54 μM (2-fold dilutions) or 1.2 nM–4.81 μM (2-fold dilutions), respectively. The labelled 4D6 antibody was then mixed with the α-synuclein samples to a final concentration of 5 nM and thereafter all samples were incubated for 30 min at 4 °C or room temperature for the α-synuclein oligomers or fibrils, respectively.

Samples were measured at room temperature in triplicate on the Fluidity One-M using a size range of 3–14 nm for the α-synuclein monomers and oligomers, and 3.7–17 nm for the α-synuclein fibrils. The KD and antibody binding site concentration for all three interactions were determined by Bayesian inference (equations below).

Equations

$$f_d = \rho_f + \frac{[B]}{[L]}(\rho_b - \rho_f)$$

f_d — fraction of labeled species that diffused into the axillary flow of the microfluidic chip

[L] — total concentration of labeled species

[B] — equilibrium concentration of bound labeled species

ρ_f — fraction of free labeled species

ρ_b — fraction of bound labeled species

$$[B] = \frac{[L] + \alpha[U] + K_D - \sqrt{([L] + \alpha[U] + K_D)^2 - 4\alpha[L][U])}}{2}$$

[U] — total concentration of binding sites in the unlabeled species

α — α is the fractional concentration of unlabeled species in the binding measurement

K_D — dissociation constant (affinity)

Fluidic Analytics